September 27, 2023 News by Margarida Maia, PhD Brain volume loss helps in judging DMT efficacy in RRMS: Review The rate of brain atrophy, or volume loss, may help in determining whether disease-modifying therapies (DMTs) are slowing disability progression in people with relapsing-remitting multiple sclerosis (RRMS), a review of data from 12 published studies found. The analysis, āBrain Atrophy as an Outcome of Disease-Modifying Therapy for…
May 16, 2023 News by Patricia Inacio, PhD Brain volume loss with Ocrevus similar to healthy aging: Study Ocrevus (ocrelizumab) reduces brain volume loss in people with relapsing forms of multiple sclerosis (MS) to levels similar to those seen in healthy aging, a small study reports. “These findings are consistent with an important role of inflammation on overall tissue loss and the role of ocrelizumab in…
November 22, 2022 News by Marisa Wexler, MS MS Patients Help Steer Guidelines for Talks About Brain Volume Loss A team of doctors, researchers, and patients has come up with a set of recommendations to help medical professionals in navigating difficult discussions with patients about brain atrophy ā or shrinkage ā with multiple sclerosis (MS). āOur goal is to minimize misunderstanding and apprehension about brain atrophy, also known…
May 25, 2022 News by Marta Figueiredo, PhD ‘Silent Progression’ in Relapsing MS Linked to Significant Brain Atrophy People with relapsing multiple sclerosis who have disability progression, but no clinical relapses, show significantly faster brain shrinkage, or atrophy, than those with a stable disease, a study shows. There were no significant differences in the brain atrophy rate between patients with progression independent of relapse activity (PIRA) and…
May 12, 2022 News by Lindsey Shapiro, PhD Disease Severity, Brain Changes Linked to Cognitive Decline Disease severity, brain volume loss, and brain lesions are able to predict later cognitive declines in people with relapsing-remitting multiple sclerosis (RRMS), a study in China found. The study, āClinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: a 2-year longitudinal study,ā…
February 17, 2022 News by Marta Figueiredo, PhD Fatigue Severity in MS Predicted by Shrinkage of Certain Brain Regions Lower-than-normal volumes of certain brain regions at disease onset ā indicating shrinkage, or atrophy, in those regions ā are significantly associated with current and future fatigue severity in people with multiple sclerosis (MS), a study in Germany shows. Some of these regions also were found to be central brain…
January 26, 2022 News by Lindsey Shapiro, PhD After Pregnancy, Women Show More Brain Lesions, Volume Loss Women with relapsing-remitting multiple sclerosis (RRMS) have more brain lesions and accelerated brain volume loss (BVL) after pregnancy compared with pre-pregnancy measurements, recent data showed. Brain lesions in the early postpartum period ā the first months following childbirth āĀ were associated with a higher risk of worsened disability and relapse…
October 18, 2021 News by Marta Figueiredo, PhD #ECTRIMS2021 ā Ublituximab Better Than Aubagio at Reducing Disability Editorās note: TheĀ Multiple Sclerosis News Today team is providing in-depth coverage of the virtual 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Oct. 13ā15. GoĀ here to see the latest stories from the conference. The investigational anti-CD20…
August 12, 2020 News by Steve Bryson, PhD Inflammation Drives Nerve Damage in Early MS, Imaging Study Shows Inflammation drives the loss of brain volume and thinning of the eye’s retina in the first five years of aĀ multiple sclerosis (MS) diagnosis, an imaging study demonstrates.Ā The findings support a therapeutic strategy of halting inflammatory activity during this initial period.Ā …
November 6, 2018 News by Patricia Inacio, PhD Diabetes, Hypertension, Smoking Linked with Brain Shrinkage in MS Patients Diabetes, hypertension, and active smoking correlate with more brain shrinkage in multiple sclerosis (MS) patients, a new study shows. The study, āAssessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case- control MRI studyā was published in the journalĀ Multiple Sclerosis and Related Disorders.
July 11, 2018 News by Jose Marques Lopes, PhD Rate of Brain Volume Loss Not Adequate as Marker of Treatment Effectiveness in MS Patients, Study Reports Brain volume loss takes place at a faster rateĀ in the first five years of multiple sclerosis than later in disease course, researchers report in a study that calls for scientists to “reconsider” ā for this and related reasons ā proposals to use volume loss as a measure of treatment efficacy…
February 8, 2018 News by Jose Marques Lopes, PhD #ACTRIMS2018 – Ozanimod Reduces MS Relapses and Brain Deterioration, Phase 3 Trial Shows Celgene’sĀ Ozanimod reduces relapsing multiple sclerosis patients’ relapses, brain lesions, and brain volume loss, a Phase 3 clinical trial shows. The company presented the results of the SUNBEAM trial atĀ theĀ ACTRIMS Forum 2018Ā convention in San Diego, Feb. 1-3. The presentation was titled āOzanimod Demonstrates Efficacy and Safety…
February 23, 2017 News by Patricia Inacio, PhD #ACTRIMS2017 – Lemtrada Maintains Durable Positive Effects in MS Without Additional Treatment Two Phase 3 clinical trials investigating the long-term effects of Lemtrada (alemtuzumab) in multiple sclerosis (MS) patients showed the drug maintained improved outcomes, even in the absence of further treatment. Both studies were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2017 Forum, held…
February 14, 2017 News by Patricia Silva, PhD Cladribine Tablets Reduce Brain Atrophy in MS Patients, Merck Study Finds EMD SorenoĀ has recently published Phase 3 clinical data showing that CladribineĀ tablets reduced the annualized rate of brain volume loss (BVL, brain atrophy) compared toĀ placebo in patients with relapsing-remitting multiple sclerosis (RRMS). The study, āReduced brain atrophy rates are associated with lower risk of disability progression…
September 21, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – MS Patients on Oral Gilenya Stick Longer with Treatment in Phase 4 Study A recent study showed that after one year, the majority of multiple sclerosis (MS) patients taking oral Gilenya (fingolimod) therapy stuck with their treatment, while a large proportion of thoseĀ usingĀ injectable disease-modifying drugs did not. The data, presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016…
May 9, 2016 News by Patricia Silva, PhD #CMSC16 – High Glutamate Levels in Brain Seen to Drive MS Progression Patients with multiple sclerosis (MS) have increased levels of the neurotransmitter glutamate in their brains, lowering the levels of N-acetylaspartate (NAA) ā a processĀ that likely leads to the loss of brain volume. The findings indicate that glutamate might be a driver of neuronal cell death and disease progression in MS,…
April 20, 2016 News by Margarida Azevedo, MSc Sanofi Genzyme Presenting New Data on Lemtrada’s Beneficial Effects, Drawn from RRMS Extension Study, at AAN 2016 Sanofi GenzymeĀ is presenting promising data regarding brain volume and retinal nerve fibers in multiple sclerosis (MS) patients ā drawn from an ongoing extension study intoĀ the disease-modifying drugĀ alemtuzumab (Lemtrada) ā at the 2016 American Academy of Neurology (AAN) Annual Meeting Ā taking place in Vancouver, Canada, through April…
February 10, 2016 News by Patricia Silva, PhD MS Study Finds Lipid Antibodies Reflect Changes in Brain Volume and Lesions Brigham and Womenās HospitalĀ researchers reported that antibodies directed at lipids are associated with magnetic resonance imaging (MRI) measures of brain degenerationĀ in patients with multiple sclerosis (MS), and may potentially serve asĀ biomarkers for monitoring disease status. While the hyperintense brain lesions detected by MRI are crucial for diagnosis and therapeutic…
October 9, 2015 News by Patricia Silva, PhD Biometrica MS Launched at ECTRIMS 2015 to Support Routine Multiple Sclerosis Care Biometrica MS, a technology that provides an easy to use service for neurologists to quantify lesion load as well as brain volume measures in clinical practice, is a web-based image analysis tool that was recently launched at the 31st Congress of the European Committee for Treatment and Research in Multiple…